Keywords: Pozen, Vimovo, AstraZeneca, FDA, Milestone
Pozen gets $20 million milestone from AstraZeneca as a result of FDA approval of Vimovo
Article | 27 May 2010
US drug firm Pozen says it has now received a $20 million milestone payment from Anglo-Swedish drug major AstraZeneca for the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
